Enabling reliable MSC expansion under animal-free conditions
Translating robust, research-grade MSC cultures into defined, GMP-ready processes can be challenging, especially when replacing serum and animal-derived reagents with animal-origin–free alternatives. Changes in culture components can affect growth, viability, and phenotype, often requiring additional optimization and validation.
In this application note, we demonstrate how GMP-grade TrypsiNNex® and Recombinant Insulin support consistent MSC expansion and trilineage differentiation under defined, serum-free conditions. Using umbilical cord–derived MSCs, the study highlights a scalable, traceable foundation for moving from research protocols to compliant manufacturing with fewer process adjustments.
Key takeaways
Together, TrypsiNNex® and Recombinant Insulin support animal-origin–free conditions that address key challenges in MSC process development, from maintaining cell quality to ensuring scalability, flexibility, and compliance:
- Rapid, consistent dissociation reduces cell handling variability and improves process reproducibility.
- Robust serum-free proliferation enables predictable expansion rates and easier scale-up planning.
- Tunable insulin concentrations allow serum-free media optimization to meet process-specific needs.
- Trilineage differentiation under animal-free conditions ensures biological consistency during GMP adaptation.
Download the application note
Learn how defined, recombinant reagents can help streamline your MSC process development and support a smoother transition to GMP manufacturing. Download the full application note by completing the form below.
